No Detail Found!

Do pharmaceutical companies selectively report clinical trial data?

Author(s)
Syed Ahmer Department of Psychiatry, The Aga Khan University, Karachi, Pakistan
Imran Ijaz Haider Department of Psychiatry, Fatima Memorial Hospital, Lahore, Pakistan
Duncan Anderson West London Mental Health NHS Trust Uxbridge road, Southall, Middlessex UB1 3EU, U.K
Pradeep Arya Specialist Registrar in Generl Adult Psychiatry St Charles Hpsital, Exmoor street, London W10DZ, U.K
Abstract
Many studies have shown that there is an association between a positive outcome of clinical trials, economic analyses and systematic reviews, and funding by the manufacturer of the drug of interest. Selective reporting of clinical trial data has been suggested as one of the possible explanations of this so-called funding bias. We conducted a review of the literature to find out if there is any evidence that this selective reporting of clinical trial data occurs. We report the several systematic reviews and cross-sectional surveys, and many case studies of this phenomenon that we found in the medical literature. We searched Medline, Embase and PsycINFO databases for this study besides hand searching BMJ from January 2003 to November 2005. We included systematic reviews, cross-sectional surveys, letters, editorials, comments or news items that referred to actual incidences of withholding, suppression, selective release or selective publication of clinical trial data by pharmaceutical companies.
Publication Details
Page(s) 338-346
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 22, Issue: 3, Year: 2006

Request the full text from PASTIC

0

Citations

0

Downloads

128

Views